| Citation: |
QIU Guoqin, CHEN Xiaojue, XU Yingyi, CHEN Jinping. Clinical Observation of Pirfenidone in Prevention and Treatment of Radiation–Induced Lung Injury in Esophageal Cancer[J]. Cancer Research on Prevention and Treatment, 2025, 52(3): 217-224. DOI: 10.3971/j.issn.1000-8578.2025.24.0592
|
To observe the effectiveness and safety of pirfenidone in the prevention and treatment of radiation-induced lung injury in esophageal cancer.
We retrospectively analyzed the data of 103 patients with esophageal cancer, of whom 53 in the combined group were treated with simultaneous chemoradiotherapy combined with pirfenidone and 50 in the control group were treated with simultaneous chemoradiotherapy only. The patients were followed up for three years to observe the treatment effects, adverse effects, and survival, as well as the incidence of radiation-induced lung injury, lung function, and changes in lung injury cytokine levels within one year after radiotherapy.
Treatment efficiency in the combined group was higher than that in the control group (86.8% vs. 70.0%, P<0.05). The two- and three-year survival rates in the combined group were 84.9% and 71.7%, respectively, which were higher than those (68.0% and 52.0%) in the control group (P<0.05). The one-, two-, and three-year disease-free survival rates in the combined group were 86.8%, 67.9%, and 47.2%, respectively, which were higher than those (62.0%, 46.0%, and 28.0%) in the control group (P<0.05). The incidence rates of radiation pneumonitis at three months, pulmonary fibrosis at six months, and one year after radiotherapy in the combined group were 22.6%, 13.2%, and 14.0%, respectively, which were lower than those (42.0%, 30.0%, and 31.8%) in the control group at the same time (P<0.05). At the end of radiotherapy and at three months, six months and one year after radiotherapy, the combined group showed higher levels of lung function indicators but lower levels of lung injury-related cytokines than the control group (P<0.05). The incidence of rash in the combined group was 18.9%, which was higher than that (2.0%) in the control group (P<0.05). However, no statistically significant difference in the incidence and severity of other adverse reactions was found between the two groups (P>0.05).
Pirfenidone not only effectively reduces radiation-induced lung injury and improves lung function in esophageal cancer patients undergoing simultaneous chemoradiotherapy, but also helps improve tumor control rates and patient survival with a good safety profile.
Competing interests: The authors declare that they have no competing interests.
| [1] |
Chen YY, Wang M, Zuo CY, et al. Nrf-2 as a novel target in radiation induced lung injury[J]. Heliyon, 2024, 10(8): e29492. doi: 10.1016/j.heliyon.2024.e29492
|
| [2] |
Dasgupta Q, Jiang A, Wen AM, et al. A human lung alveolus-on-a-chip model of acute radiation-induced lung injury[J]. Nat Commun, 2023, 14(1): 6506. doi: 10.1038/s41467-023-42171-z
|
| [3] |
Farh ME, Kim HJ, Kim SY, et al. Transcriptional changes in radiation-induced lung injury: a comparative analysis of two radiation doses for preclinical research[J]. Int J Mol Sci, 2024, 25(7): 3766. doi: 10.3390/ijms25073766
|
| [4] |
Amirkhosravi A, Mirtajaddini Goki M, Heidari MR, et al. Combination of losartan with pirfenidone: a protective anti-fibrotic against pulmonary fibrosis induced by bleomycin in rats[J]. Sci Rep, 2024, 14(1): 8729. doi: 10.1038/s41598-024-59395-8
|
| [5] |
Türkkan G, Willems Y, Hendriks LEL, et al. Idiopathic pulmonary fibrosis: Current knowledge, future perspectives and its importance in radiation oncology[J]. Radiother Oncol, 2021, 155: 269-277. doi: 10.1016/j.radonc.2020.11.020
|
| [6] |
Chen C, Zeng BW, Xue D, et al. Pirfenidone for the prevention of radiation-induced lung injury in patients with locally advanced oesophageal squamous cell carcinoma: Aprotocol for a randomised controlled trial[J]. BMJ Open, 2022, 12(10): e060619. doi: 10.1136/bmjopen-2021-060619
|
| [7] |
Freites-Martinez A, Santana N, Arias-Santiago S, et al. Using the common terminology criteria for adverse events(CTCAE-Versión 5.0) to Evaluate the severity of events of anticancer therapies[J]. Actas Dermosifiliogr(Engl Ed), 2021, 112(1): 90-92. doi: 10.1016/j.ad.2019.05.009
|
| [8] |
Lencioni R, Llovet JM. Modified RECIST (mRECIST) assessment for hepatocellular carcinoma[J]. Semin Liver Dis, 2010, 30(1): 52-60. doi: 10.1055/s-0030-1247132
|
| [9] |
Inoo H, Sakanaka K, Fujii K, et al. Association of volumetric-modulated arc therapy with radiation pneumonitis in thoracic esophageal cancer[J]. J Radiat Res, 2022, 63(4): 646-656. doi: 10.1093/jrr/rrac021
|
| [10] |
Beach TA, Finkelstein JN, Chang CY. Epithelial responses in radiation-induced lung injury (RILI) allow chronic inflammation and fibrogenesis[J]. Radiat Res, 2023, 199(5): 439-451.
|
| [11] |
Shi XY, Zhu YQ, Ting CJ, et al. Single-cell transcriptomic analysis of radiation-induced lung injury in rat[J]. Biomol Biomed, 2024, 24(5): 1331-1349. doi: 10.17305/bb.2024.10357
|
| [12] |
Jahnke L, Perrenoud V, Zandi S, et al. Modulation of extracellular matrix composition and chronic inflammation with pirfenidone promotes scar reduction in retinal wound repair[J]. Cells, 2024, 13(2): 164. doi: 10.3390/cells13020164
|
| [13] |
AI-Kuraishy H M, Batiha GES, Faidah H, et al. Pirfenidone and post-Covid-19 pulmonary fibrosis: invoked again for realistic goals[J]. Inflammopharmacology, 2022, 30(6): 2017-2026. doi: 10.1007/s10787-022-01027-6
|
| [14] |
Amirkhosravi A, Heidari MR, Karami-Mohajeri S, et al. Losartan enhances the suppressive effect of pirfenidone on the bleomycin-induced epithelial-mesenchymal transition and oxidative stress in A549 cell line[J]. Iran J Basic Med Sci, 2023, 26(8): 972-978.
|
| [15] |
Gutiérrez J, López D, Sandoval A S, et al. P-3 Pirfenidone prevents obesity-associated nonalcoholic steatohepatitis and cardiac fibrosis through hormonal reprogramming[J]. Ann Hepatol, 2024, 29(1 suppl): 101190.
|
| [16] |
Munoz-Espinosa LE, Torre A, Cisneros L, et al. Prolonged-release pirfenidone in patients with compensated cirrhosis. Final results of the multicenter study ODISEA, controlled against placebo, plus standardized care 2023[J]. Ann Hepatol, 2024, 29(2 suppl): 101472.
|
| [17] |
Mohamed HE, Abdelhady MA, Elmaghraby AM, et al. Empagliflozin and pirfenidone confer renoprotection through suppression of glycogen synthase kinase-3β and promotion of tubular regeneration in rats with induced metabolic syndrome[J]. Toxicol Appl Pharm, 2024, 485: 116892. doi: 10.1016/j.taap.2024.116892
|
| [18] |
Schreiber J, Schütte W, Koerber W, et al. Clinical course of mild-to-moderate idiopathic pulmonary fibrosis during therapy with pirfenidone: results of the non-interventional study AERplus[J]. Pneumologie, 2024, 78(4): 236-243. doi: 10.1055/a-2267-2074
|
| [19] |
Ying HJ, Fang M, Hang QQ, et al. Pirfenidone modulates macrophage polarization and ameliorates radiation-induced lung fibrosis by inhibiting the TGF-β1/Smad3 pathway[J]. J Cell Mol Med, 2021, 25(18): 8662-8675. doi: 10.1111/jcmm.16821
|
| [20] |
Moustafa M, Lipson KE, Akbarpour M, et al. Late intervention with radiation-induced lung fibrosis -comparing pamrevlumab anti-CTGF therapy vs. pirfenidone vs. nintedanib as mono-, dual- and triple-therapy combinations[J]. Int J Radiat Oncol, 2020, 108(3S): S76.
|
| [21] |
Mummudi N, David S, Tandon S, et al. PROphylactic pirfenidone for prevention of radiation induced pneumonitis in patients with lung cancer (PROPeR study)[J]. J Thorac Oncol, 2023, 18 (11 suppl): S299.
|
| [22] |
Manie MF, Fawzy HM, El-Sayed El-SM. Hydroxytyrosol alleviates methotrexate-induced pulmonary fibrosis in rats: involvement of TGF-β1, tissue factor, and VEGF[J]. Biol Pharm Bull, 2024, 47(1): 303-310. doi: 10.1248/bpb.b23-00477
|
| [23] |
Monroy HC, Arceo S, Cabral AG, et al. P-21 fibrosis development and malignancies are delayed by pirfenidone while increasing SIRT1 nuclear translocation and histone 3 deacetylations in a hepatocarcinoma model[J]. Ann Hepatol, 2024, 29(1 suppl): 101208.
|
| [24] |
Igbo BT, Jentsch C, Linge A, et al. Correlation of microscopic tumor extension with tumor microenvironment in esophageal cancer patients[J]. Strahlenther Onkol, 2024, 200(7): 595-604. doi: 10.1007/s00066-024-02234-6
|
| [25] |
Florescu DN, Boldeanu MV, Șerban RE, et al. Correlation of the pro-inflammatory cytokines IL-1β, IL-6, and TNF-α, inflammatory markers, and tumor markers with the diagnosis and prognosis of colorectal cancer[J]. Life(Basel), 2023, 13(12): 2261.
|
| [26] |
Fernandes S, Oliver-De La Cruz, Morazzo S, et al. TGF-β induces matrisome pathological alterations and EMT in patient-derived prostate cancer tumoroids[J]. Matrix Biol, 2024, 125: 12-30. doi: 10.1016/j.matbio.2023.11.001
|
| [27] |
Ilson DH. Emerging evidence for VEGF and immune checkpoint inhibition in oesophagogastric cancer[J]. Lancet Gastroenterol Hepatol, 2022, 7(3): 200-201. doi: 10.1016/S2468-1253(21)00428-3
|
| [28] |
Wang G, Zhou XW, Guo ZL, et al. The Anti-fibrosis drug Pirfenidone modifies the immunosuppressive tumor microenvironment and prevents the progression of renal cell carcinoma by inhibiting tumor autocrine TGF-β[J]. Cancer Biol Ther, 2022, 23(1): 150-162. doi: 10.1080/15384047.2022.2035629
|
| [29] |
Miranda-Roblero HO, Monroy-Ramírez HC, Galicia-Moreno M, et al. P-43 Pirfenidone prevents neoplastic lesions development by oxidative, fibrogenic, antiproliferative and epigenetic mechanisms regulation in a model of chemical hepatocarcinogenesis [J]. Ann Hepatol, 2023, 28(1 suppl): 100945.
|
| [30] |
Luo DQ, Zeng XL, Zhang SL, et al. Pirfenidone suppressed triple-negative breast cancer metastasis by inhibiting the activity of the TGF-β/SMAD pathway[J]. J Cell Mol Med, 2023, 27(3): 456-469. doi: 10.1111/jcmm.17673
|
| [31] |
Zhang S, Wang Y, Luo D, et al. Pirfenidone inhibits TGF-β1-induced metabolic reprogramming during epithelial-mesenchymal transition in non-small cell lung cancer[J]. J Cell Mol Med, 2024, 28(3): e18059. doi: 10.1111/jcmm.18059
|
Figures(2) / Tables(9)
This work is licensed under a Creative Commons Attribution 3.0 License.
Copyright © Editorial Department of Cancer Prevention Research 鄂公网安备 42011102005013号 鄂ICP备2022015867号
Supported by: Beijing Renhe Information Technology Co., Ltd. 
DownLoad: